Neomera BioLab, Inc.

Neomera BioLab is a peptide therapeutics company building a differentiated drug discovery platform to redefine chronic pain treatment and unlock next-generation therapeutics for complex disorders. The company addresses a major challenge in drug discovery, achieving precise control and selectivity across difficult target classes, especially membrane proteins. By unifying AI and experimental biology into a single workflow, Neomera has generated proprietary binding data that enables highly selective modulation, accelerating the development of lab-validated peptide therapeutics versus conventional methods. A key innovation is Neomera’s lipid vesicle-based expression system, which stabilizes complex membrane proteins, including GPCRs and ion channels, making previously inaccessible targets druggable. Its initial programs include state-independent sodium channel inhibitors for chronic pain and controlled modulators for complex disorders such as depression, addiction, and relapse.